Quality of life among testis cancer survivors

Urologic Oncology: Seminars and Original Investigations

Volumn 33, Issue 9, 2015, Pages 413-419

  Gilligan, Timothy ^a  

^a TAUSSIG CANCER INSTITUTE   (United States)

Author keywords

Fatigue; Germ cell tumors; Neuropathy; Quality of life; Survivors; Survivorship; Testis cancer

Indexed keywords

BLEOMYCIN; CISPLATIN; ETOPOSIDE; OXALIPLATIN; PACLITAXEL;

ANXIETY; CANCER FATIGUE; CANCER SURVIVOR; DEPRESSION; EXERCISE; HEARING IMPAIRMENT; HUMAN; NEUROPATHY; NEUROTOXICITY; OTOTOXICITY; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; QUALITY OF LIFE; RAYNAUD PHENOMENON; RELAXATION TRAINING; REVIEW; SOCIAL PSYCHOLOGY; TESTIS CANCER; TINNITUS; COMPLICATION; MALE; PSYCHOLOGY; SURVIVOR; TESTIS TUMOR;

HUMANS; MALE; QUALITY OF LIFE; SURVIVORS; TESTICULAR NEOPLASMS;

EID: 84940467352     PISSN: 10781439     EISSN: 18732496     Source Type: Journal    
DOI: 10.1016/j.urolonc.2015.05.018     Document Type: Review

References (57)

1. Mykletun A., Dahl A.A., Haaland C.F., Bremnes R., Dahl O., Klepp O., et al. Side effects and cancer-related stress determine quality of life in long-term survivors of testicular cancer. J Clin Oncol 2005, 23:3061-3068.
2. Fleer J., Hoekstra H.J., Sleijfer D.T., Tuinman M.A., Klip E.C., Hoekstra-Weebers J.E. Quality of life of testicular cancer survivors and the relationship with sociodemographics, cancer-related variables, and life events. Support Care Cancer 2006, 14:251-259.
3. Tuinman M.A., Fleer J., Hoekstra H.J., Sleijfer D.T., Hoekstra-Weebers J.E. Quality of life and stress response symptoms in long-term and recent spouses of testicular cancer survivors. Eur J Cancer 2004, 40:1696-1703.
4. Rossen P.B., Pedersen A.F., Zachariae R., von der Maase H. Health-related quality of life in long-term survivors of testicular cancer. J Clin Oncol 2009, 27:5993-5999.
5. Vidrine D.J., Hoekstra-Weebers J.E., Hoekstra H.J., Tuinman M.A., Marani S., Gritz E.R. The effects of testicular cancer treatment on health-related quality of life. Urology 2010, 75:636-641.
6. Alacacioglu A., Ulger E., Varol U., Yavuzsen T., Akyol M., Yildiz Y., et al. Sexual satisfaction, anxiety, depression and quality of life in testicular cancer survivors. Med Oncol 2014, 31:43.
7. Dahl A.A., Mykletun A., Fossa S.D. Quality of life in survivors of testicular cancer. Urol Oncol 2005, 23:193-200.
8. Kim C., McGlynn K.A., McCorkle R., Erickson R.L., Niebuhr D.W., Ma S., et al. Quality of life among testicular cancer survivors: a case-control study in the United States. Qual Life Res 2011, 20:1629-1637.
9. Fleer J., Hoekstra H.J., Sleijfer D.T., Hoekstra-Weebers J.E. Quality of life of survivors of testicular germ cell cancer: a review of the literature. Support Care Cancer 2004, 12:476-486.
10. Fossa S.D., Chen J., Dores G.M., McGlynn K.A., Schonfeld S.J., Travis L.B. Long-term non-cancer mortality among 39,657 one-year testicular cancer survivors. Proc Am Soc Clin Oncol 2006, 24:4508.
11. Travis L.B., Fossa S.D., Schonfeld S.J., McMaster M.L., Lynch C.F., Storm H., et al. Second cancers among 40,576 testicular cancer patients: focus on long-term survivors. J Natl Cancer Inst 2005, 97:1354-1365.
12. Joly F., Heron J.F., Kalusinski L., Bottet P., Brune D., Allouache N., et al. Quality of life in long-term survivors of testicular cancer: a population-based case-control study. J Clin Oncol 2002, 20:73-80.
13. Wiechno P., Demkow T., Kubiak K., Sadowska M., Kaminska J. The quality of life and hormonal disturbances in testicular cancer survivors in Cisplatin era. Eur Urol 2007, 52:1448-1454.
14. Grov E.K., Fossa S.D., Bremnes R.M., Dahl O., Klepp O., Wist E., et al. The personality trait of neuroticism is strongly associated with long-term morbidity in testicular cancer survivors. Acta Oncol 2009, 1-8.
15. Smith A.B., King M., Butow P., Luckett T., Grimison P., Toner G.C., et al. The prevalence and correlates of supportive care needs in testicular cancer survivors: a cross-sectional study. Psychooncology 2013, 22:2557-2564.
16. Skoogh J., Steineck G., Johansson B., Wilderang U., Stierner U. Psychological needs when diagnosed with testicular cancer: findings from a population-based study with long-term follow-up. BJU Int 2013, 111:1287-1293.
17. Fossa S.D., Dahl A.A., Loge J.H. Fatigue, anxiety, and depression in long-term survivors of testicular cancer. J Clin Oncol 2003, 21:1249-1254.
18. Dahl A.A., Haaland C.F., Mykletun A., Bremnes R., Dahl O., Klepp O., et al. Study of anxiety disorder and depression in long-term survivors of testicular cancer. J Clin Oncol 2005, 23:2389-2395.
19. Eberhard J., Stahl O., Cohn-Cedermark G., Cavallin-Stahl E., Giwercman Y., Rastkhani H., et al. Emotional disorders in testicular cancer survivors in relation to hypogonadism, androgen receptor polymorphism and treatment modality. J Affect Disord 2010, 122:260-266.
20. Skaali T., Fossa S.D., Bremnes R., Dahl O., Haaland C.F., Hauge E.R., et al. Fear of recurrence in long-term testicular cancer survivors. Psychooncology 2009, 18:580-588.
21. Orre I.J., Fossa S.D., Murison R., Bremnes R., Dahl O., Klepp O., et al. Chronic cancer-related fatigue in long-term survivors of testicular cancer. J Psychosom Res 2008, 64:363-371.
22. Orre I.J., Murison R., Dahl A.A., Ueland T., Aukrust P., Fossa S.D. Levels of circulating interleukin-1 receptor antagonist and C-reactive protein in long-term survivors of testicular cancer with chronic cancer-related fatigue. Brain Behav Immun 2009, 23:868-874.
23. Denlinger C.S., Ligibel J.A., Are M., Baker K.S., Demark-Wahnefried W., Friedman D.L., et al. Survivorship: fatigue, version 1.2014. J Natl Compr Canc Netw 2014, 12:876-887.
24. Bower J.E. Cancer-related fatigue-mechanisms, risk factors, and treatments. Nat Rev Clin Oncol 2014, 11:597-609.
25. Bower J.E., Bak K., Berger A., Breitbart W., Escalante C.P., Ganz P.A., et al. Screening, assessment, and management of fatigue in adult survivors of cancer: an American Society of Clinical oncology clinical practice guideline adaptation. J Clin Oncol 2014, 32:1840-1850.
26. Mishra S.I., Scherer R.W., Snyder C., Geigle P., Gotay C. Are exercise programs effective for improving health-related quality of life among cancer survivors? A systematic review and meta-analysis. Oncol Nurs Forum 2014, 41:E326-E342.
27. Mitchell S.A., Hoffman A.J., Clark J.C., DeGennaro R.M., Poirier P., Robinson C.B., et al. Putting evidence into practice: an update of evidence-based interventions for cancer-related fatigue during and following treatment. Clin J Oncol Nurs 2014, 18:38-58.
28. Yennurajalingam S., Bruera E. Review of clinical trials of pharmacologic interventions for cancer-related fatigue: focus on psychostimulants and steroids. Cancer J 2014, 20:319-324.
29. Mitchell S.A., Beck S.L., Hood L.E., Moore K., Tanner E.R. Putting evidence into practice: evidence-based interventions for fatigue during and following cancer and its treatment. Clin J Oncol Nurs 2007, 11:99-113.
30. Meneses-Echavez J.F., Gonzalez-Jimenez E., Ramirez-Velez R. Supervised exercise reduces cancer-related fatigue: a systematic review. J Physiother 2015, 61:3-9.
31. Gielissen M.F., Verhagen C.A., Bleijenberg G. Cognitive behaviour therapy for fatigued cancer survivors: long-term follow-up. Br J Cancer 2007, 97:612-618.
32. Gielissen M.F., Verhagen S., Witjes F., Bleijenberg G. Effects of cognitive behavior therapy in severely fatigued disease-free cancer patients compared with patients waiting for cognitive behavior therapy: a randomized controlled trial. J Clin Oncol 2006, 24:4882-4887.
33. Yun Y.H., Lee K.S., Kim Y.W., Park S.Y., Lee E.S., Noh D.Y., et al. Web-based tailored education program for disease-free cancer survivors with cancer-related fatigue: a randomized controlled trial. J Clin Oncol 2012, 30:1296-1303.
34. Bokemeyer C., Berger C.C., Hartmann J.T., Kollmannsberger C., Schmoll H.J., Kuczyk M.A., et al. Analysis of risk factors for cisplatin-induced ototoxicity in patients with testicular cancer. Br J Cancer 1998, 77:1355-1362.
35. Strumberg D., Brugge S., Korn M.W., Koeppen S., Ranft J., Scheiber G., et al. Evaluation of long-term toxicity in patients after cisplatin-based chemotherapy for non-seminomatous testicular cancer. Ann Oncol 2002, 13:229-236.
36. Delanian S., Lefaix J.L., Pradat P.F. Radiation-induced neuropathy in cancer survivors. Radiother Oncol 2012, 105:273-282.
37. Brydoy M., Oldenburg J., Klepp O., Bremnes R.M., Wist E.A., Wentzel-Larsen T., et al. Observational study of prevalence of long-term Raynaud-like phenomena and neurological side effects in testicular cancer survivors. J Natl Cancer Inst 2009, 101:1682-1695.
38. Glendenning J.L., Barbachano Y., Norman A.R., Dearnaley D.P., Horwich A., Huddart R.A. Long-term neurologic and peripheral vascular toxicity after chemotherapy treatment of testicular cancer. Cancer 2010, 116:2322-2331.
39. Hartmann J.T., Kollmannsberger C., Kanz L., Bokemeyer C. Platinum organ toxicity and possible prevention in patients with testicular cancer. Int J Cancer 1999, 83:866-869.
40. Fossa S.D., de Wit R., Roberts J.T., Wilkinson P.M., de Mulder P.H., Mead G.M., et al. Quality of life in good prognosis patients with metastatic germ cell cancer: a prospective study of the European Organization for Research and Treatment of Cancer Genitourinary Group/Medical Research Council Testicular Cancer Study Group (30941/TE20). J Clin Oncol 2003, 21:1107-1118.
41. Kelley M.R., Jiang Y., Guo C., Reed A., Meng H., Vasko M.R. Role of the DNA base excision repair protein, APE1 in cisplatin, oxaliplatin, or carboplatin induced sensory neuropathy. PLoS One 2014, 9:e106485.
42. Boehmerle W., Huehnchen P., Peruzzaro S., Balkaya M., Endres M. Electrophysiological, behavioral and histological characterization of paclitaxel, cisplatin, vincristine and bortezomib-induced neuropathy in C57Bl/6 mice. Sci Rep 2014, 4:6370.
43. Brouwers E.E., Huitema A.D., Boogerd W., Beijnen J.H., Schellens J.H. Persistent neuropathy after treatment with cisplatin and oxaliplatin. Acta Oncol 2009, 48:832-841.
44. Wolf S., Barton D., Kottschade L., Grothey A., Loprinzi C. Chemotherapy-induced peripheral neuropathy: prevention and treatment strategies. Eur J Cancer 2008, 44:1507-1515.
45. Albers J.W., Chaudhry V., Cavaletti G., Donehower R.C. Interventions for preventing neuropathy caused by cisplatin and related compounds. Cochrane Database Syst Rev 2014, 3:CD005228.
46. Cleeland C.S., Farrar J.T., Hausheer F.H. Assessment of cancer-related neuropathy and neuropathic pain. Oncologist 2010, 15(Suppl. 2):13-18.
47. Argyriou A.A., Chroni E., Koutras A., Iconomou G., Papapetropoulos S., Polychronopoulos P., et al. A randomized controlled trial evaluating the efficacy and safety of vitamin E supplementation for protection against cisplatin-induced peripheral neuropathy: final results. Support Care Cancer 2006, 14:1134-1140.
48. Pace A., Savarese A., Picardo M., Maresca V., Pacetti U., Del Monte G., et al. Neuroprotective effect of vitamin E supplementation in patients treated with cisplatin chemotherapy. J Clin Oncol 2003, 21:927-931.
49. Pace A., Giannarelli D., Galie E., Savarese A., Carpano S., Della Giulia M., et al. Vitamin E neuroprotection for cisplatin neuropathy: a randomized, placebo-controlled trial. Neurology 2010, 74:762-766.
50. Kottschade L.A., Sloan J.A., Mazurczak M.A., Johnson D.B., Murphy B.P., Rowland K.M., et al. The use of vitamin E for the prevention of chemotherapy-induced peripheral neuropathy: results of a randomized phase III clinical trial. Support Care Cancer 2011, 19:1769-1777.
51. Hershman D.L., Lacchetti C., Dworkin R.H., Lavoie Smith E.M., Bleeker J., Cavaletti G., et al. Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol 2014, 32:1941-1967.
52. Rao R.D., Michalak J.C., Sloan J.A., Loprinzi C.L., Soori G.S., Nikcevich D.A., et al. Efficacy of gabapentin in the management of chemotherapy-induced peripheral neuropathy: a phase 3 randomized, double-blind, placebo-controlled, crossover trial (N00C3). Cancer 2007, 110:2110-2118.
53. Smith E.M., Pang H., Cirrincione C., Fleishman S., Paskett E.D., Ahles T., et al. Effect of duloxetine on pain, function, and quality of life among patients with chemotherapy-induced painful peripheral neuropathy: a randomized clinical trial. J Am Med Assoc 2013, 309:1359-1367.
54. Prete M., Fatone M.C., Favoino E., Perosa F. Raynaud's phenomenon: from molecular pathogenesis to therapy. Autoimmun Rev 2014, 13:655-667.
55. Boekhout A.H., Maunsell E., Pond G.R., Julian J.A., Coyle D., Levine M.N., et al. A survivorship care plan for breast cancer survivors: extended results of a randomized clinical trial. J Cancer Surviv 2015, [Epub ahead of print].
56. Brennan M.E., Gormally J.F., Butow P., Boyle F.M., Spillane A.J. Survivorship care plans in cancer: a systematic review of care plan outcomes. Br J Cancer 2014, 111:1899-1908.
57. Grunfeld E., Julian J.A., Pond G., Maunsell E., Coyle D., Folkes A., et al. Evaluating survivorship care plans: results of a randomized, clinical trial of patients with breast cancer. J Clin Oncol 2011, 29:4755-4762.